Galecto Management
Management criteria checks 3/4
Galecto's CEO is Hans Schambye, appointed in Jan 2020, has a tenure of 4.25 years. total yearly compensation is $1.39M, comprised of 33.9% salary and 66.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $36.03K. The average tenure of the management team and the board of directors is 4 years and 4.3 years respectively.
Key information
Hans Schambye
Chief executive officer
US$1.4m
Total compensation
CEO salary percentage | 33.9% |
CEO tenure | 4.3yrs |
CEO ownership | 0.2% |
Management average tenure | 4yrs |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?
Jan 10Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely
May 17Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
Feb 01Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer
Oct 19Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Oct 19Galecto GAAP EPS of -$0.67 beats by $0.02
Jul 29We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Jun 30Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?
Mar 10Galecto: Selling At Cash Value
Dec 19We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Nov 18Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Jul 07Galecto EPS misses by $0.07
May 04We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth
Mar 23Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?
Jan 29Galecto EPS misses by $41.65
Dec 11CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$38m |
Sep 30 2023 | n/a | n/a | -US$46m |
Jun 30 2023 | n/a | n/a | -US$52m |
Mar 31 2023 | n/a | n/a | -US$58m |
Dec 31 2022 | US$1m | US$473k | -US$62m |
Sep 30 2022 | n/a | n/a | -US$61m |
Jun 30 2022 | n/a | n/a | -US$60m |
Mar 31 2022 | n/a | n/a | -US$55m |
Dec 31 2021 | US$3m | US$512k | -US$52m |
Sep 30 2021 | n/a | n/a | -US$42m |
Jun 30 2021 | n/a | n/a | -US$44m |
Mar 31 2021 | n/a | n/a | -US$43m |
Dec 31 2020 | US$4m | US$387k | -US$35m |
Sep 30 2020 | n/a | n/a | -US$57m |
Jun 30 2020 | n/a | n/a | -US$48m |
Mar 31 2020 | n/a | n/a | -US$42m |
Dec 31 2019 | US$479k | US$360k | -US$42m |
Compensation vs Market: Hans's total compensation ($USD1.39M) is above average for companies of similar size in the US market ($USD674.64K).
Compensation vs Earnings: Hans's compensation has been consistent with company performance over the past year.
CEO
Hans Schambye (57 yo)
4.3yrs
Tenure
US$1,394,817
Compensation
Dr. Hans T. Schambye, MD, Ph D, serves as Member of Board of Directors at BioInnovation Institute. Dr. Schambye is Co-Founder and has been Chief Executive Officer at Galecto, Inc. since 2020 and serves as...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 4.3yrs | US$1.39m | 0.19% $ 36.0k | |
Chief Financial Officer | 4yrs | US$889.11k | 0.044% $ 8.2k | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Senior VP | 2.9yrs | no data | 0.015% $ 2.7k |
4.0yrs
Average Tenure
45yo
Average Age
Experienced Management: GLTO's management team is considered experienced (4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 4.3yrs | US$1.39m | 0.19% $ 36.0k | |
Independent Chairman of the Board | 4.3yrs | US$151.13k | 0.035% $ 6.6k | |
Independent Director | 3.9yrs | US$177.52k | 0% $ 0 | |
Independent Director | 4.3yrs | US$80.56k | 0% $ 0 | |
Independent Director | 3.9yrs | US$75.56k | 0.018% $ 3.3k | |
Independent Director | 4.3yrs | no data | no data | |
Independent Director | 3.4yrs | US$82.38k | 0% $ 0 | |
Member of Clinical Advisory Board – Liver cirrhosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data |
4.3yrs
Average Tenure
56yo
Average Age
Experienced Board: GLTO's board of directors are considered experienced (4.3 years average tenure).